

E1 1 ~~34~~. An antibody, or functional fragment thereof, comprising a  $V_H$  CDR1 referenced as SEQ ID NO:34; a  $V_H$  CDR2 referenced as SEQ ID NO:102; a  $V_H$  CDR3 referenced as SEQ ID NO:106; a  $V_L$  CDR1 referenced as SEQ ID NO:108; a  $V_L$  CDR2 referenced as SEQ ID NO:112; and a  $V_L$  CDR3 referenced as SEQ ID NO:90, said antibody or functional fragment thereof having integrin  $\alpha_v\beta_3$  binding activity, integrin  $\alpha_v\beta_3$  binding specificity or integrin  $\alpha_v\beta_3$ -inhibitory activity.

E2 5 ~~38~~. An antibody, or a functional fragment thereof, comprising a  $V_H$  CDR1 referenced as SEQ ID NO:34; a  $V_H$  CDR2 referenced as SEQ ID NO:102; a  $V_H$  CDR3 referenced as SEQ ID NO:106; a  $V_L$  CDR1 referenced as SEQ ID NO:110; a  $V_L$  CDR2 referenced as SEQ ID NO:112; and a  $V_L$  CDR3 referenced as SEQ ID NO:90, said antibody or functional fragment thereof having integrin  $\alpha_v\beta_3$  binding activity, integrin  $\alpha_v\beta_3$  binding specificity or integrin  $\alpha_v\beta_3$ -inhibitory activity.

E3 9 ~~42~~. An antibody, or a functional fragment thereof, comprising a  $V_H$  CDR1 referenced as SEQ ID NO:34; a  $V_H$  CDR2 referenced as SEQ ID NO:104; a  $V_H$  CDR3 referenced as SEQ ID NO:106; a  $V_L$  CDR1 referenced as SEQ ID NO:110; a  $V_L$  CDR2 referenced as SEQ ID NO:112; and a  $V_L$  CDR3 referenced as SEQ ID NO:90, said antibody or functional fragment thereof having integrin  $\alpha_v\beta_3$  binding activity, integrin  $\alpha_v\beta_3$  binding specificity or integrin  $\alpha_v\beta_3$ -inhibitory activity.

Please add the following new claims.

<sup>13</sup>~~46~~. (New) An antibody, or a functional fragment thereof, comprising a CDR selected from the group consisting of a V<sub>H</sub> CDR2 referenced as SEQ ID NO:104; a V<sub>H</sub> CDR3 referenced as SEQ ID NO:106; and a V<sub>L</sub> CDR1 referenced as SEQ ID NO:110, said antibody or functional fragment thereof having integrin  $\alpha_v\beta_3$  binding activity, integrin  $\alpha_v\beta_3$  binding specificity or integrin  $\alpha_v\beta_3$ -inhibitory activity.

E4 <sup>14</sup>~~47~~. (New) The antibody of claim <sup>13</sup>~~46~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>15</sup>~~48~~. (New) A nucleic acid encoding the antibody or functional fragment of claim <sup>13</sup>~~46~~.

<sup>16</sup>~~49~~. (New) The nucleic acid molecule of claim <sup>15</sup>~~48~~, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:103, SEQ ID NO:105, and SEQ ID NO:109.

<sup>17</sup>~~50~~. (New) The antibody or functional fragment of claim <sup>13</sup>~~46~~, wherein said CDR is a V<sub>H</sub> CDR2 referenced as SEQ ID NO:104.

<sup>18</sup>~~51~~. (New) The antibody of claim <sup>17</sup>~~50~~, wherein said functional fragment is Fv.

152

E

Inventors: Huse and Wu  
Serial No.: 09/339,922  
Filed: June 24, 1999  
Page 4

<sup>19</sup>52. (New) The antibody of claim <sup>17</sup>50, wherein said functional fragment is Fab.

<sup>20</sup>53. (New) The antibody of claim <sup>17</sup>50, wherein said functional fragment is F(ab)<sub>2</sub>.

<sup>21</sup>54. (New) The antibody of claim <sup>17</sup>50, wherein said functional fragment is scFV.

E4  
cont.  
<sup>22</sup>55. (New) A nucleic acid encoding the antibody or functional fragment of claim <sup>17</sup>50.

<sup>23</sup>56. (New) The nucleic acid molecule of claim <sup>22</sup>55, wherein said nucleic acid molecule comprises the nucleotide sequence SEQ ID NO:103.

<sup>24</sup>57. (New) The antibody or functional fragment of claim <sup>13</sup>46, wherein said CDR is a V<sub>H</sub> CDR3 referenced as SEQ ID NO:106.

<sup>25</sup>58. (New) The antibody of claim <sup>24</sup>57, wherein said functional fragment is Fv.

<sup>26</sup>59. (New) The antibody of claim <sup>24</sup>57, wherein said functional fragment is Fab.

<sup>27</sup>60. (New) The antibody of claim <sup>24</sup>57, wherein said functional fragment is F(ab)<sub>2</sub>.

153

8

Inventors: Huse and Wu  
Serial No.: 09/339,922  
Filed: June 24, 1999  
Page 5

<sup>28</sup>~~61~~. (New) The antibody of claim <sup>27</sup>~~57~~, wherein said functional fragment is scFV.

<sup>24</sup>~~62~~. (New) A nucleic acid encoding the antibody or functional fragment of claim <sup>24</sup>~~57~~.

<sup>30</sup>~~63~~. (New) The nucleic acid molecule of claim <sup>29</sup>~~62~~, wherein said nucleic acid molecule comprises the nucleotide sequence SEQ ID NO:105.

54  
cont.  
<sup>13</sup><sup>31</sup>~~64~~. (New) The antibody or functional fragment of claim <sup>13</sup>~~46~~, wherein said CDR is a V<sub>L</sub> CDR1 referenced as SEQ ID NO:110.

<sup>32</sup>~~65~~. (New) The antibody of claim <sup>31</sup>~~64~~, wherein said functional fragment is Fv.

<sup>33</sup>~~66~~. (New) The antibody of claim <sup>31</sup>~~64~~, wherein said functional fragment is Fab.

<sup>34</sup>~~67~~. (New) The antibody of claim <sup>31</sup>~~64~~, wherein said functional fragment is F(ab)<sub>2</sub>.

<sup>35</sup>~~68~~. (New) The antibody of claim <sup>31</sup>~~64~~, wherein said functional fragment is scFV.

<sup>36</sup>~~69~~. (New) A nucleic acid encoding the antibody or functional fragment of claim <sup>31</sup>~~64~~.

154

8

Inventors: Huse and Wu  
Serial No.: 09/339,922  
Filed: June 24, 1999  
Page 6

<sup>37</sup>~~70~~. (New) The nucleic acid molecule of claim <sup>36</sup>~~69~~, wherein said nucleic acid molecule comprises the nucleotide sequence SEQ ID NO:109.

<sup>38</sup>~~71~~. (New) The antibody of claim <sup>✓</sup>~~35~~, wherein said functional fragment is Fv.

<sup>39</sup>~~72~~. (New) The antibody of claim <sup>✓</sup>~~35~~, wherein said functional fragment is Fab.

<sup>40</sup>~~73~~. (New) The antibody of claim <sup>✓</sup>~~35~~, wherein said functional fragment is F(ab)<sub>2</sub>.

<sup>41</sup>~~74~~. (New) The antibody of claim <sup>✓</sup>~~35~~, wherein said functional fragment is scFV.

<sup>42</sup>~~75~~. (New) The antibody of claim <sup>6</sup>~~39~~, wherein said functional fragment is Fv.

<sup>43</sup>~~76~~. (New) The antibody of claim <sup>6</sup>~~39~~, wherein said functional fragment is Fab.

<sup>44</sup>~~77~~. (New) The antibody of claim <sup>6</sup>~~39~~, wherein said functional fragment is F(ab)<sub>2</sub>.

<sup>45</sup>~~78~~. (New) The antibody of claim <sup>6</sup>~~39~~, wherein said functional fragment is scFV.

155

E

Inventors: Huse and Wu  
Serial No.: 09/339,922  
Filed: June 24, 1999  
Page 7

<sup>46</sup><sub>79</sub>. (New) The antibody of claim <sup>10</sup>~~43~~, wherein said functional fragment is Fv.

<sup>47</sup><sub>80</sub>. (New) The antibody of claim <sup>10</sup>~~43~~, wherein said functional fragment is Fab.

EY  
CONT.  
<sup>48</sup><sub>81</sub>. (New) The antibody of claim <sup>10</sup>~~43~~, wherein said functional fragment is F(ab)<sub>2</sub>.

<sup>49</sup><sub>82</sub>. (New) The antibody of claim <sup>10</sup>~~43~~, wherein said functional fragment is scFV.

#### REMARKS

Claims 1-45 are pending. Claims 1-20 and 25-45 are under examination. Claims 1-33 are canceled herein without prejudice to Applicants pursuing the subject matter of these claims in a related application. Claims 34, 38 and 42 have been amended to correct antecedent basis. New claims 46-82 have been added. Support for new claims 46-82 can be found throughout the application and the claims as filed. In particular, support for new claims 46-70 can be found, for example, in original claims 1, 2, 13 and 14; on page 15, lines 21-28; and in Tables 11-14 on pages 104-107, respectively. Support for new claims 71-74, 75-78, and 79-82 can be found in original claims 28, 30 and 32, respectively. Accordingly, these amendments and new claims do not raise an issue of new matter and entry thereof is respectfully requested.

156

8